中文
For process chemists, liquid bromine is notoriously troublesome due to its high corrosivity and volatility. Its weighing, feeding and tail gas treatment all pose major operational challenges. Pyridinium tribromide (CAS: 39416-48-3) locks bromine into a stable solid complex, featuring easy dosing, improved handling safety and tunable bromination selectivity. It has been adopted in the synthetic routes of many pharmaceuticals, including mifepristone and sunitinib.
Mifepristone and Brinzolamide: Bromination Steps in Established Drugs
As documented in BenchChem technical resources, pyridinium tribromide is used for the key bromination step in the synthesis of mifepristone, which is applied for medical termination of pregnancy and Cushing’s syndrome treatment. It also participates in the preparation of brinzolamide, a glaucoma therapeutic agent. Acting as a stable solid bromine source, it replaces liquid bromine to achieve selective bromination and improves operational safety and process reproducibility.
Sunitinib: Bromination of the Indole Scaffold
In the conventional synthetic route of the anticancer drug sunitinib, 5-fluoroindole reacts with pyridinium tribromide (formed in situ from pyridine, bromine and hydrogen bromide) to yield 5-fluoro-3,3-dibromo-2-indolinone as the key intermediate. Subsequent palladium-catalyzed hydrodehalogenation delivers the core framework. This bromination step lays the foundation for the following condensation and cyclization reactions.
Bupropion: Greener Bromination in Flow Chemistry
The synthesis of the antidepressant bupropion demonstrates the advantages of pyridinium tribromide in sustainable process development. According to Reaction Chemistry & Engineering, researchers applied polymer-supported pyridinium tribromide (1.5 eq.) in a packed-bed continuous-flow reactor for bromination. This protocol avoids hazardous liquid bromine under mild conditions and greatly enhances safety, offering a practical template for continuous bromination manufacturing.
Oxandrolone: Process Upgrade Boosting Overall Yield from 8% to 45%
In the industrial process development of the anabolic steroid oxandrolone, literature in Organic Process Research & Development reports that pyridinium tribromide bromides methylandrostanolone to afford the 2-bromoketone intermediate in around 80% yield, with minimal dehydration side reactions. Combined with subsequent elimination and ozonolysis, the overall yield was raised dramatically from 8% in the original route to 45%, representing a benchmark case of process optimization.
From antiviral and anticancer agents to endocrine medicines, pyridinium tribromide enables accurate and safe bromination, serving as a valuable reagent in modern pharmaceutical synthesis. Shunxiang Pharmaceutical provides high-purity pyridinium tribromide with consistent batch-to-batch quality and controlled specifications, delivering reliable support for pharmaceutical process development and scale-up production.